维普期刊资源整合服务平台（V6.5）

25篇 您的检索式：作者名="PIPERDI B"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Phase Ⅱ study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma显示文摘	LU C PEREZ-SOLER R PIPERDI B	2005	J Clin Oncol2005，23，15：	1
2	KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy显示文摘	Siddiqui A D Piperdi B	2010	Ann Surg Oncol2010，17，4：	1
3	KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy显示文摘	Siddiqui A D Piperdi B	2010	Ann Surg Oncol2010，17，：	1
4	A phase Ⅱ trial of cetuximab,gemcitabine,5-Fluorouracil,and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma显示文摘	Cetin V Piperdi B Bathini V	2013	Gastrointest Cancer Res:GCR2013，6，41：	1
5	Schedule-dependent interaction between epidermal growth factor inlathitors (EGFRI)and G2/M blocking chemotherapeutic agents(G2/M) on human NSCLC cell in vitro显示文摘	Piperdi B Ling YH Kroog G	2004	J Clin Oncol2004，，：	1
6	Phase- I/显示文摘	PIPERDI B WALSH WV BRADLEY K et 01	2012	J Thorac Oncol2012，7，6：	1
7	A phase Ⅱ trial of cetuximab,gemcitabine,5-fluorouracil,and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma显示文摘	Cetin V Piperdi B Bathini V	2013	Gastrointest Cancer Res2013，6，41：	1
8	Phase 1/ study of the pro- teasomeinhibitorbortezomib (PS-341,Velcade)in chemo therapy-naive patients with advanced stage nonsmall cell lung cancer (NSCLC) 显示文摘	Li T Ho L Piperdi B	2010	Lung Cancer2010，68，1：	1
9	KRAS mutation in colon cancer:a mark- er of resistance to EGFR-I therapy 显示文摘	Siddiqui AD Piperdi B	2010	Ann Surg Oncol2010，17，4：	1
10	Phase I/II study of bortezomib in combination with carboplatin and beva- cizumab as first line therapy in patients with advanced non-small cell lung cancer(NSCLC)显示文摘	Piperdi B Walsh WV Bradley K	2012	J Thorac Oncol2012，7，6：	1
11	Schedule - dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/M) on human NSCLC cell in vitro显示文摘	PIPERDI B LING Y H KROOG G	2004	J Clin Oncol2004，，：	1
12	Targeting angiogenesis in squamous non-small cell lung cancer 显示文摘	Piperdi B Merla A Perez-Soler R	2014	Drugs2014，74，4：	1
13	Monoclonal antibodies to Mycobacterium tuberculosis CDC 1551 reveal subcellular localization of MPT51显示文摘	Al-sayyed B Piperdi S Yuan X	2007	Tuberculosis2007，，87：	1
14	Role of erlotinib in the treat- ment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients 显示文摘	Piperdi B Perez-Soler R	2012	Drugs2012，72，1：	1
15	Phase Ⅱ study of the proteasome inhibitor bortezomib in chemotherapy-naive patients with advanced stage non-small cell lung cancer 显示文摘	Li T He L Piperdi B	2009	Lung Cancer2009，68，1：	1
16	KRAS mutation in colon cancer:a marker of resistance to EGFR-I therapy 显示文摘	Siddiqui AD Piperdi B	2010	Ann Surg On- col2010，17，4：	1
17	Long Term Disease Control With Sunitinib in a Patient With Metastatic Pancreatic Neuroendocrine Tumor (NET) Associated With Von Hippel-Lindau Syndrome (VHL) 显示文摘	Ali T Kandil D and Piperdi B	2012	Pancreas2012，41，3：	1
18	Targeting angiogenesis in squa- mous non-small cell lung cancer显示文摘	Piperdi B Merla A Perez-Soler R	2014	Drugs2014，74，4：	1
19	Kras mutation in colon cancer: a marker of resistance to EGFR-I therapy显示文摘	Siddiqui AD Piperdi B	2010	Ann Surg Oncol2010，17，4：	1
20	Phase-Ⅰ /Ⅱ study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer显示文摘	Piperdi B Walsh WV Bradley K		0，，06：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示